<DOC>
	<DOCNO>NCT01809184</DOCNO>
	<brief_summary>This trial conduct Europe . The aim first human dose trial investigate safety , tolerability , pharmacodynamic ( effect investigate drug body ) pharmacokinetic ( exposure trial drug body ) property NNC0148-0000-0287 ( insulin 287 ) GIPETÂ® I tablet formulation healthy subject .</brief_summary>
	<brief_title>A Trial Investigating Safety , Tolerability , Pharmacokinetics Pharmacodynamics NNC0148-0000-0287 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Body mass index 18.028.0 kg/m^2 Subject consider healthy base medical history , physical examination , result vital sign , electrocardiogram ( ECG ) clinical laboratory test perform screen visit , judge investigator Known suspect hypersensitivity trial product relate product Previous participation trial . Participation define randomised Presence clinically significant acute gastrointestinal symptom ( e.g . nausea , vomit , heartburn diarrhoea ) within 2 week prior dose , judge investigator Any chronic disorder severe disease , opinion investigator , might jeopardise subject 's safety compliance protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>